Comparative Pharmacology
Head-to-head clinical analysis: IMPAVIDO versus NEBUPENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPAVIDO versus NEBUPENT.
IMPAVIDO vs NEBUPENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miltefosine, the active ingredient in IMPAVIDO, is an alkylphosphocholine with antileishmanial activity. It interacts with cell membrane phospholipids, inhibits cytochrome c oxidase, and induces apoptosis-like cell death in Leishmania parasites. It also modulates host immune responses.
Nebupent (pentamidine isethionate) is an antimicrobial agent that inhibits the synthesis of DNA, RNA, phospholipids, and proteins in protozoa. Its mechanism may involve interference with polyamine synthesis and inhibition of dihydrofolate reductase.
60 mg/kg body weight per day (2.5 mg/kg per hour) by intravenous infusion over 6 hours, up to a maximum of 150 mg/day, for 21 days.
300 mg via inhalation once every 4 weeks for prophylaxis of Pneumocystis jirovecii pneumonia.
None Documented
None Documented
Terminal elimination half-life is approximately 16-21 days in adults; may be longer in severe hepatic impairment.
Terminal elimination half-life: 6-9 hours (prolonged in renal impairment; clinical context: supports once-daily dosing for treatment, but prophylaxis may require reduced frequency in renal dysfunction)
Primarily renal (over 90% as unchanged drug); fecal excretion is minimal (<5%).
Renal: approximately 90% as unchanged drug; biliary/fecal: minimal (<5%)
Category C
Category C
Antiprotozoal
Antiprotozoal, Inhaled